| Article ID | Journal | Published Year | Pages | File Type | 
|---|---|---|---|---|
| 8444450 | European Journal of Cancer | 2013 | 6 Pages | 
Abstract
												While ALK translocations are not present in oesophageal cancer, ALK amplifications are common events with comparable rates in SCC and AC. Since ALK amplified breast cancer cells were shown to respond to ALK inhibitors, ALK amplified oesophageal cancers might be considered as possible candidates for therapies targeting ALK.
											Related Topics
												
													Life Sciences
													Biochemistry, Genetics and Molecular Biology
													Cancer Research
												
											Authors
												Sebastian F. Schoppmann, Berthold Streubel, Peter Birner, 
											